High impact
MAB2026063004
Pennsylvania Medicaid (DHS)·Effective Jul 6, 2026
Pennsylvania Medical Assistance (MA) program has updated prior authorization requirements for Cytokine and CAM Antagonist medications, effective July 6, 2026. The policy establishes comprehensive clinical review guidelines for determining medical necessity, including new requirements for specialist consultation, tuberculosis/hepatitis B screening, mental health evaluation for specific drugs, and disease-specific criteria for Crohn's disease, ulcerative colitis, rheumatoid arthritis, and juvenile idiopathic arthritis. All pharmacies and prescribers enrolled in MA must follow these updated requirements for fee-for-service and managed care beneficiaries.